Clinical trial
Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor…
NCT00084396 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00084396 |
|---|---|
| Title | Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer |
| Official title | A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | letrozole, conventional surgery |
| Enrollment | 115 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Sep 1, 2016 |
| First posted | Jun 11, 2004 |
| Last update posted | Sep 26, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: